These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25460570)

  • 41. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
    Green DJ; Pagel JM; Nemecek ER; Lin Y; Kenoyer A; Pantelias A; Hamlin DK; Wilbur DS; Fisher DR; Rajendran JG; Gopal AK; Park SI; Press OW
    Blood; 2009 Aug; 114(6):1226-35. PubMed ID: 19515724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
    Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
    Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Leonard JP; Siegel JA; Goldsmith SJ
    Cancer Invest; 2003 Apr; 21(2):241-52. PubMed ID: 12743990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.
    Fujiwara K; Koyama K; Suga K; Ikemura M; Saito Y; Hino A; Iwanari H; Kusano-Arai O; Mitsui K; Kasahara H; Fukayama M; Kodama T; Hamakubo T; Momose T
    PLoS One; 2015; 10(5):e0125468. PubMed ID: 26017283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
    O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
    Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation.
    Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW
    Blood; 1995 Feb; 85(4):1122-31. PubMed ID: 7849300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
    Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide.
    Janssen ML; Pels W; Massuger LF; Oyen WJ; Boonstra H; Corstens FH; Boerman OC
    Int J Gynecol Cancer; 2003; 13(5):607-13. PubMed ID: 14675343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice.
    Anderson-Berg WT; Squire RA; Strand M
    Cancer Res; 1987 Apr; 47(7):1905-12. PubMed ID: 3469024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
    O'Donnell RT; DeNardo SJ; DeNardo GL; Miers L; Lamborn KR; Kukis DL; Meyers FJ
    Prostate; 2000 Aug; 44(3):187-92. PubMed ID: 10906734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.